XTERA Introduces Managed Wealth-Growth Platform

XTERA
New York City, NY, June 04, 2025 (GLOBE NEWSWIRE) --XTERA, a new financial platform built for everyday individuals, has launched its professionally managed wealth-building service, designed to provide steady, daily returns without requiring users to become financial experts or take on unnecessary risk.
In a time when side hustles and high-risk trading platforms dominate personal finance conversations, XTERA offers a more practical alternative: a way to grow money in the background, with oversight from experienced professionals and complete transparency.
'We built XTERA for people who are tired of having to choose between financial growth and free time,' said a spokesperson for XTERA. 'Our goal is to give users a simple way to participate in modern financial markets without needing to constantly check charts or learn investing on their own.'
How It Works:
XTERA allocates user funds into a diversified portfolio, managed by real traders with expertise in today's key sectors—such as AI, Web3, and other emerging industries. Users do not need to take any active role. Returns are calculated daily, and members have access to a live dashboard to track performance in real time. Funds are accessible at all times with no holding periods, penalties, or lock-ins.
XTERA is available exclusively within The Code, a private community focused on accessible and sustainable financial tools. An invite is required to join, keeping the platform focused on members who are genuinely looking for long-term, stable financial growth.
Built for Regular People
XTERA is specifically designed for individuals with full-time jobs, family commitments, or limited bandwidth to explore complex financial products. It requires no prior investing experience, and the setup is simple. Most importantly, it doesn't rely on users spending extra hours working to earn more.
About XTERA
XTERA is a financial platform designed to give everyday people a smarter, more accessible way to grow their wealth. Built exclusively for members of The Code, it offers daily earning potential through expertly managed portfolios, without the stress of doing it all yourself. With real traders behind the scenes and full transparency through live dashboards, XTERA puts the user in control while doing the hard work for them. No lock-ins. No complicated setups. Just a modern, flexible path to building your financial future.Join the community today.Company Number: 4047 LLC 2025Richmond Hill, P.O. Box 2897, Kingstown St. Vincent and The Grenadines Prisha Elgouharipr@xtera.org
Attachment
XTERA
CONTACT: Company Number: 4047 LLC 2025 Richmond Hill, P.O. Box 2897, Kingstown St. Vincent and The Grenadines Prisha Elgouhari pr@xtera.orgSign in to access your portfolio

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

10 minutes ago

• Yahoo

Investors in IHH Healthcare Berhad (KLSE:IHH) have seen notable returns of 38% over the past five years

When we invest, we're generally looking for stocks that outperform the market average. And in our experience, buying the right stocks can give your wealth a significant boost. For example, the IHH Healthcare Berhad (KLSE:IHH) share price is up 28% in the last 5 years, clearly besting the market return of around 6.4% (ignoring dividends). On the other hand, the more recent gains haven't been so impressive, with shareholders gaining just 12%, including dividends. So let's assess the underlying fundamentals over the last 5 years and see if they've moved in lock-step with shareholder returns. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. Over half a decade, IHH Healthcare Berhad managed to grow its earnings per share at 114% a year. The EPS growth is more impressive than the yearly share price gain of 5% over the same period. So it seems the market isn't so enthusiastic about the stock these days. You can see below how EPS has changed over time (discover the exact values by clicking on the image). Dive deeper into IHH Healthcare Berhad's key metrics by checking this interactive graph of IHH Healthcare Berhad's earnings, revenue and cash flow. As well as measuring the share price return, investors should also consider the total shareholder return (TSR). The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. We note that for IHH Healthcare Berhad the TSR over the last 5 years was 38%, which is better than the share price return mentioned above. This is largely a result of its dividend payments! It's good to see that IHH Healthcare Berhad has rewarded shareholders with a total shareholder return of 12% in the last twelve months. That's including the dividend. Since the one-year TSR is better than the five-year TSR (the latter coming in at 7% per year), it would seem that the stock's performance has improved in recent times. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. Before forming an opinion on IHH Healthcare Berhad you might want to consider these 3 valuation metrics. If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Malaysian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo

14 minutes ago

• Yahoo

Scholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug Trial

We recently published a list of These 10 Stocks Boast Double-Digit Gains Amid Boring Market. Scholar Rock Holding Corporation (NASDAQ:SRRK) is one of the best-performing stocks on Thursday. Scholar Rock jumped by 16.6 percent on Wednesday to close at $36.32 apiece as investor sentiment was bolstered by the positive results from the second phase of its weight loss drug trial. In a statement, Scholar Rock Holding Corporation (NASDAQ:SRRK) said the trial, which aims to assess its drug candidate apitegromab's combination with tirzepatide, was generally well tolerated, leading to higher quality weight loss as compared with taking tirzepatide alone. According to Scholar Rock Holding Corporation (NASDAQ:SRRK), apitegromab therapy in combination with tirzepatide resulted in the preservation of 4.2 pounds of lean mass compared with tirzepatide alone. 'While this is an exciting development for our platform, we remain focused on preparing for the launch of apitegromab, and following its potential approval in SMA, we look forward to studying it in a range of neuromuscular diseases with high unmet need,' said Scholar Rock Holding Corporation (NASDAQ:SRRK) President and CEO Akshay Vaishnaw, adding that he was looking forward to exploring its potential in various rare, severe debilitating neuromuscular disorders. A scientist holding a flask of liquid in a laboratory, highlighting the research and discoveries of new treatments. 'We remain on track to file an IND application for SRK-439 in the second half of this year to support the first in human study,' he said. While we acknowledge the potential of SRRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Wall Street Journal

17 minutes ago

• Wall Street Journal

Trump Says He's Nearing a Possible Deal With Harvard

President Trump said his administration was 'working closely' with Harvard University and could announce a deal within the next week. The White House and Harvard have been locked in battle since late March. Trump has pulled billions in federal funds over antisemitism and DEI concerns, tried to block Harvard's ability to enroll international students and threatened its tax-exempt status. Harvard has sued the administration, saying the government has violated its First Amendment rights.